Menu
Not yet recruiting NCT07377552

Association Analysis of Depression and Asthma

— Observational Depression，Asthma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Depression，Asthma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Association Analysis of Depression and Asthma: A Retrospective Cross-Sectional and Mendelian Randomization Study

Overview

Main Studies Integrate retrospective studies, observational studies, and Mendelian randomization (MR) study methods to systematically analyze the strength and direction of the association between depression and asthma. Explore whether a causal relationship exists between depression and asthma, and identify potential confounding factors and effect modifiers. Secondary Studies Screen for key confounding variables that affect the association between depression and asthma (e.g., age, gender, lifestyle, comorbidities, etc.). Analyze the correlation between depression and the severity of asthma. Verify the stability of instrumental variables (IVs) and the reliability of causal effects in the MR study. Key Term Supplementary Explanations Effect modifiers: Factors that alter the strength or direction of the association between an exposure (e.g., depression) and an outcome (e.g., asthma) (e.g., certain genes or medications may modify how depression influences asthma risk). Instrumental variables (IVs): Genetic variants used in MR studies that are associated with the exposure (e.g., depression-related SNPs) but not directly associated with the outcome (e.g., asthma) except through the exposure, helping to reduce confounding and infer causality.

Primary outcome measures

  • Integrate retrospective studies, observational studies, and Mendelian randomization (MR) methods to systematically analyze the strength of the association between depression and asthma. [Time frame: November 1, 2025 - October 31, 2026]
  • Explore whether a causal relationship exists between depression and asthma, and identify potential confounding factors. [Time frame: November 1, 2025 - October 31, 2026]
  • Screen for key confounding variables that influence the association between depression and asthma. [Time frame: November 1, 2025 - October 31, 2026]
  • Analyze the correlation between depression and the severity of asthma. [Time frame: November 1, 2025 - October 31, 2026]
Secondary outcome measures (1)
  • Verify the stability of instrumental variables (IVs) in the Mendelian Randomization (MR) study. [Time frame: November 1, 2025 - October 31, 2026]

Eligibility criteria

Inclusion Criteria For Retrospective Study

  • Age ≥ 18 years old
  • Complete medical records, including demographic characteristics (age, gender, ethnicity, etc.), clinical diagnosis information (diagnosis time of depression/asthma, diagnostic basis), treatment plans (medication type, dosage), and follow-up records
  • Depression diagnosis conforms to relevant clinical criteria; asthma diagnosis conforms to Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 Edition)

For MR Study (GWAS Data)

  • Data have undergone strict quality control
  • Study participants are of European ancestry (to reduce population stratification bias)
  • Clear division of case group and control group, as well as available sample size information

Exclusion Criteria For Retrospective Study

  • Comorbidity with other severe mental illnesses (e.g., schizophrenia, bipolar affective disorder)
  • Comorbidity with severe respiratory diseases (e.g., chronic obstructive pulmonary disease \[COPD\], pulmonary fibrosis, lung cancer)
  • Comorbidity with severe organ failure (e.g., heart, liver, or kidney failure)
  • Lack of key information in medical records (e.g., diagnosis time, core symptoms, treatment plan)

For MR Study (IVs Screening)

  • Single nucleotide polymorphisms (SNPs) with an association significance P-value ≥ 5×10-⁸ with the exposure (depression/asthma)
  • SNPs with high linkage disequilibrium (LD, r² ≥ 0.001, distance ≤ 10000 kb)
  • SNPs located in coding regions or those that may affect gene expression regulation (at risk of horizontal pleiotropy)
  • SNPs with an F-statistic < 10 (at risk of weak instrumental variable bias)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07377552 · ZWu

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗